Levicept

With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability. Levicept Ltd is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. We are progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.
Type
Private
HQ
Sandwich, GB
Founded
2012
Levicept was founded in 2012 and is headquartered in Sandwich, GB

Key People at Levicept

Simon Westbrook

Simon Westbrook

CEO

Levicept Locations

Sandwich, GB

Levicept Metrics

Levicept Summary

Founding Date

2012

Total Funding

$16.1 M

Latest funding size

$3.87 M

Time since last funding

about 2 years

Investors

Levicept's latest funding round of $3.87 M was in October 2014. In total, Levicept has raised $16.1 M.

Levicept Company Life

You may also be interested in